These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26723762)

  • 21. Development and receding of a coronary artery aneurysm after implantation of a fully bioresorbable scaffold.
    Nakatani S; Ishibashi Y; Suwannasom P; Grundeken MJ; Høj Christiansen E; Onuma Y; Serruys PW;
    Circulation; 2015 Feb; 131(8):764-7. PubMed ID: 25712060
    [No Abstract]   [Full Text] [Related]  

  • 22. Very late bioresorbable vascular scaffold thrombosis: a new clinical entity.
    Azzalini L; Al-Hawwas M; L'Allier PL
    EuroIntervention; 2015 May; 11(1):e1-2. PubMed ID: 25982486
    [No Abstract]   [Full Text] [Related]  

  • 23. In-Stent Dissection Causes No Flow During Percutaneous Coronary Intervention.
    Yashima F; Yuasa S; Maekawa Y; Kimura M; Akita K; Yanagisawa R; Tanaka M; Hayashida K; Kawakami T; Kanazawa H; Fujita J; Fukuda K
    JACC Cardiovasc Interv; 2016 Jan; 9(1):102-103. PubMed ID: 26685075
    [No Abstract]   [Full Text] [Related]  

  • 24. In-Stent Restenosis: Is the Future Bioresorbable?
    Claessen BE; Feldman DN
    JACC Cardiovasc Interv; 2024 Aug; 17(15):1837-1839. PubMed ID: 39142759
    [No Abstract]   [Full Text] [Related]  

  • 25. First-in-man demonstration of complete bioresorbable vascular scaffold resorption after treatment of in-stent restenosis.
    Moscarella E; Ielasi A; Cortese B; De Angelis MC; Varricchio A
    Coron Artery Dis; 2017 Aug; 28(5):437-439. PubMed ID: 28574901
    [No Abstract]   [Full Text] [Related]  

  • 26. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ruptured neoatherosclerosis presenting as a large intrastent neointimal dissection.
    Rivero F; Cuesta J; Benedicto A; Bastante T; Alfonso F
    JACC Cardiovasc Interv; 2014 Nov; 7(11):e169-70. PubMed ID: 25459046
    [No Abstract]   [Full Text] [Related]  

  • 29. Complex, diffuse in-stent atherosclerosis over a decade following bare metal stenting.
    Lau JK; Alcock RF; Brieger D; Lowe HC
    Coron Artery Dis; 2015 Aug; 26 Suppl 1():e69-70. PubMed ID: 26247273
    [No Abstract]   [Full Text] [Related]  

  • 30. Bioresorbable scaffolds for the treatment of in-stent restenosis.
    Dörr O; Liebetrau C; Wiebe J; Hecker F; Rixe J; Möllmann H; Hamm C; Nef H
    Heart Vessels; 2015 Mar; 30(2):265-9. PubMed ID: 24390727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation.
    Indolfi C; Mongiardo A; Spaccarotella C; Caiazzo G; Torella D; De Rosa S
    Circ Cardiovasc Imaging; 2014 Jul; 7(4):755-7. PubMed ID: 25027457
    [No Abstract]   [Full Text] [Related]  

  • 32. Bioresorbable drug-eluting scaffold restenosis: Larger Is Probably Better.
    Belardi JA; Albertal M
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1162-3. PubMed ID: 25999275
    [No Abstract]   [Full Text] [Related]  

  • 33. A broken promise: 4-year optical coherence tomography follow-up of a bioresorbable vascular scaffold.
    Versaci F; Vizzari G; Prati F; Biondi-Zoccai G
    J Cardiovasc Med (Hagerstown); 2020 May; 21(5):398-400. PubMed ID: 32243342
    [No Abstract]   [Full Text] [Related]  

  • 34. Magmaris very late in-scaffold restenosis: Has the "black boxes" nightmare come back?
    Bayón J; Santás-Álvarez M; Ocaranza-Sánchez R; González-Juanatey C
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):E174-E176. PubMed ID: 31763757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stent failure due to simultaneous aggressive neoatherosclerosis of first- and current-generation drug-eluting stents.
    Komukai K; Bernelli C; Sirbu V; Guagliumi G
    EuroIntervention; 2015 Nov; 11(7):e1-2. PubMed ID: 26603864
    [No Abstract]   [Full Text] [Related]  

  • 36. Optical coherence tomography assessment of late intra-scaffold dissection: a new challenge of bioresorbable scaffolds.
    Ohno Y; Mangiameli A; Attizzani GF; Capodanno D; Tamburino C
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):e11-2. PubMed ID: 25499307
    [No Abstract]   [Full Text] [Related]  

  • 37. In-stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus-eluting stent to treat a long de novo coronary lesion with small distal vessel diameter.
    Obata JE; Nakamura T; Kitta Y; Saito Y; Sano K; Fujioka D; Kawabata K; Kugiyama K
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E777-87. PubMed ID: 23378231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Insulin Resistance on Neointimal Tissue Proliferation after 2nd-Generation Drug-Eluting Stent Implantation.
    Komatsu T; Yaguchi I; Komatsu S; Nakahara S; Kobayashi S; Sakai Y; Taguchi I
    Tex Heart Inst J; 2015 Aug; 42(4):327-32. PubMed ID: 26413014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial.
    Nakatani S; Onuma Y; Ishibashi Y; Muramatsu T; Iqbal J; Zhang YJ; van Geuns RJ; Ormiston JA; Serruys PW
    EuroIntervention; 2015 Mar; 10(11):1288-98. PubMed ID: 24572936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds.
    Gogas BD; Garcia-Garcia HM; Onuma Y; Muramatsu T; Farooq V; Bourantas CV; Serruys PW
    JACC Cardiovasc Interv; 2013 Mar; 6(3):211-21. PubMed ID: 23517830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.